Humans haven’t been back to the moon since the Apollo moons program ended over five decade ago. The reasons why go beyond science, according to experts.

The Apollo era was defined by ambition, success, and unexpected challenges. While NASA’s focus shifted after Apollo 11, the near-catastrophic Apollo 13 mission became one of history’s greatest ...

With the Cold War fueling the space race, NASA faced its greatest test—landing humans on the Moon. The Apollo Program overcame setbacks, perfected lunar orbit, and built the Lunar Module, leading to ...

The Artemis II mission, which will return US astronauts to lunar space, has run into problems that have critics demanding NASA remove the crew from the flight for safety reasons. The bigger question ...

Greece’s energy regulator has launched two new auctions under the Apollo Program, covering up to 200 MW of solar with storage and a separate 400 MW wind tender, marking the scheme’s first operational ...

Apollo Hospitals announced the successful completion of over 8,000 robotic-assisted surgeries across multiple specialities, marking a ...

Amy Shira Teitel says past Moon missions delivered a clear purpose and impact, while Artemis II lacks clarity, ...

NASA's Artemis II mission returns astronauts to the Moon with first female and African American crew members. Explore their profiles and historic adventure ahead.

The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...

Standard Chartered has named Peter Burrill as interim group chief financial officer, marking an abrupt leadership change at ...

Detailed price information for Disc Medicine Inc (IRON-Q) from The Globe and Mail including charting and trades.

Guidance for Q1 2026 is revenue of $45 million to $49 million and an adjusted EBITDA margin between negative 10% and negative 4%. The company expects continued improvement in both revenue and margins ...